Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype

Ананьева, Л. П.; Авдеев, С. Н.; Тюрин, И. Е.; Лила, А. М.; Zagrebneva, Alena I.; Маслянский, А. Л.; Терпигорев, С. А.; Степанян, И. В.; Лашина, Е. Л.; Васильева, О. В.; Лукина, О. С.; Першина, Е. С.; Клименко, А. А.; Шостак, Н. А.; Насонов, Евгений Львович

doi:10.47360/1995-4484-2020-631-636

Cited by 3 publications

(1 citation statement)

References 46 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Прогрессирующий фиброз легочной ткани отмечается у 18-32% всех больных с интерстициальными болезнями легких [1]. Это прежде всего идиопатический легочный фиброз, а также другие идиопатические пневмониты, хронический гиперсенситивный пневмонит, саркоидоз, поражение легких при иммуновоспалительных ревматических заболеваниях, васкулитах [2][3][4][5][6][7].…”

unclassified

Modern problems of interstitial lung diseases in children

Мизерницкий

Лев

2021

Ross. vestn. perinatol. pediatr.

View full text Add to dashboard Cite

Interstitial lung diseases refer to a large group of diseases with a severe course and unfavorable prognosis, since the most forms of these diseases cause irreversible fibrosis of the lung tissue and severe respiratory failure. Lung transplantation remains the only way to save the patient’s.The article highlights the current state of the problem, achievements and prospects in the study, diagnosis and approaches to the treatment of interstitial lung diseases in children. The authors emphasize that this direction is one of the most relevant in pediatric pulmonology and clinical medicine in general.

show abstract

unclassified

Modern problems of interstitial lung diseases in children

Мизерницкий

Лев

2021

Ross. vestn. perinatol. pediatr.

View full text Add to dashboard Cite

show abstract

Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology

Насонов

Ananieva²,

Avdeev

2022

Naučno-praktičeskaâ revmatologiâ

Self Cite

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is an immune-mediated rheumatic disease (IMRDs) characterized by chronic erosive arthritis and systemic damage to internal organs, leading to early disability and reduced life expectancy in patients. A particularly important place among the systemic manifestations of RA is occupied by interstitial lung diseases (ILD) – the most severe form of pulmonary pathology in RA, defined as RA-ILD, which is pathogenetically associated with risk factors (smoking, etc.) and autoimmune mechanisms underlying RA. RA-ILD is a subtype of RA characterized by a severe course and a poor prognosis и неблагоприятным прогнозом. The review presents new data regarding risk factors and biomarkers for RA-ILD; modern diagnostic capabilities based on the use of functional lung tests, high-resolution computed tomography, ultrasound examination of the lungs. Particular attention is paid to the efficacy and safety of pharmacotherapy, including methotrexate, biologics, JAK inhibitors, and antifibrotic therapy. An algorithm for the pharmacotherapy of RA-ILD has been proposed.

show abstract

Clinical and immunological variants of ANCA-associated systemic vasculitis: a look at the pulmonary fibrosis in microscopic polyangiitis with anti-myeloperoxidase antibodies and rheumatoid factor. Literature review and own observation

Бекетова

Golovina²,

Авдеева³

2023

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

Depending on the epitope specificity of antineutrophil cytoplasmic antibodies (ANCA) and the presence or absence of a granulomatous inflammation. Patients with ANCA-associated vasculitis (AAV) show variability in clinical manifestations and prognosis depending on the epitope specificity of ANCA and the presence or absence of granulomatous inflammation. In this regard, it is important to identify the clinical and immunological phenotypes of AAV and a personalized approach to treatment. Microscopic polyangiitis (MPA) with antibodies to myeloperoxidase (aMPO) has a relatively high incidence of lung involvement and pulmonary fibrosis. We present our own clinical case of pulmonary fibrosis in MPA with aMPO and rheumatoid factor. Literature data are discussed. In cases of early arthritis and interstitial pneumonia, the possibility of AAV should be considered, a detailed examination is necessary to identify pathognomonic signs of AAV, including asymptomatic ones. Before prescribing immunosuppressants, the epitope specificity of ANCA should be determined. Treatment with rituximab, mycophenolate mofetil and nintedanib is discussed.

show abstract

Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype

Cited by 3 publications

References 46 publications

Modern problems of interstitial lung diseases in children

Modern problems of interstitial lung diseases in children

Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology

Clinical and immunological variants of ANCA-associated systemic vasculitis: a look at the pulmonary fibrosis in microscopic polyangiitis with anti-myeloperoxidase antibodies and rheumatoid factor. Literature review and own observation

Contact Info

Product

Resources

About